FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 77 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $57,000 | +18.8% | 17,123 | +8.3% | 0.00% | – |
| Q3 2019 | $48,000 | +45.5% | 15,814 | +15.5% | 0.00% | – |
| Q2 2019 | $33,000 | +13.8% | 13,694 | +76.5% | 0.00% | – |
| Q1 2019 | $29,000 | -32.6% | 7,757 | -35.2% | 0.00% | – |
| Q4 2018 | $43,000 | +26.5% | 11,968 | +102.8% | 0.00% | – |
| Q3 2018 | $34,000 | +100.0% | 5,900 | +72.5% | 0.00% | – |
| Q2 2018 | $17,000 | -45.2% | 3,420 | -43.0% | 0.00% | – |
| Q1 2018 | $31,000 | – | 6,004 | +200033.3% | 0.00% | – |
| Q4 2017 | $0 | – | 3 | 0.0% | 0.00% | – |
| Q3 2017 | $0 | -100.0% | 3 | -95.9% | 0.00% | – |
| Q4 2015 | $1,000 | -87.5% | 73 | -93.4% | 0.00% | – |
| Q3 2015 | $8,000 | -52.9% | 1,102 | -32.1% | 0.00% | – |
| Q2 2015 | $17,000 | – | 1,623 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
| DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
| Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
| DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
| Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
| SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
| Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
| Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
| Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |